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Abstract
Background: Ferumoxytol is a safe and effective parenteral
therapy used for the treatment of iron deficiency anaemia
that has recently been approved for use in North America and
in Europe.
Methods: Ferumoxytol consists of a superparamagnetic iron
oxide (SPIO) core, which causes T1, T2 and T2* shortening
effects, and a carbohydrate shell, which results in a
prolonged intravascular half life.
Results: These properties are under-reported and not well
recognised. They can interfere with MRI interpretation, poten-
tially masking enhancement and rendering examinations non-
diagnostic or simulating pathologic disease states. Both radi-
ologists and non-radiologist physicians must consider the po-
tential interaction of ferumoxytol with MRI when interpreting
and prescribing MRI examinations in their patients.
Main Messages
• Ferumoxytol has recently been approved for the treatment
of iron deficiency anaemia.
• Ferumoxytol is a small iron oxide particle with prolonged
intravascular half life and T1, T2 and T2* shortening effects.
• Administration of ferumoxytol can mask enhancement,
rendering MRI studies potentially non-diagnostic.
• Ferumoxytol can mimic diseases such as haemosiderosis,
haemochromatosis and superficial siderosis.
• Ferumoxytol interactions with MRI must be recognised by
radiologists and non-radiologist physicians.
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Abbreviations
SPIO Super-paramagnetic iron oxide particle
RES Reticulo-endothelial cell system
GRE Gradient recalled echo
FSE Fast spin echo
Case presentation
A 54-year-old male patient with nonalcoholic steatohepatitis
(NASH) cirrhosis presented for surveillance with magnetic
resonance imaging (MRI) of the liver to screen for hepato-
cellular carcinoma in the setting of a routine pre-transplant
workup. The patient had iron deficiency anaemia and re-
ceived parenteral ferumoxytol (second intravenous dose of
510 mg) 3 days prior to the MRI examination. MRI was
performed using our institution’s standard high-risk liver
protocol on a 3.0-T MRI scanner (Discovery 750w,
General Electric Medical Systems, Milwaukee, WI). Pulse
sequences included: axial and coronal T2-weighted single-
shot fast spin echo (ssFSE), axial T2-weighted fast recovery
fast spin echo (FRFSE), axial 3D in- and out-of-phase gra-
dient recalled echo (GRE), B50 and B500 diffusion-
weighted imaging with an apparent diffusion coefficient
map, and pre- and dynamic post-contrast fat-suppressed 3D
T1-weighted GRE sequences (LAVA), including arterial,
portal venous and equilibrium phases. Gadobutrol
(Gadovist, Bayer Inc., Toronto, ON) was administered to
obtain the post-contrast imaging. The MRI study showed
interval changes from the baseline examination performed
15 months prior. In the interval there was a marked reduction
in signal intensity of the liver and spleen on T2 ssFSE
sequences suggesting iron overload, which had not been
present on the previous examination (Fig. 1). Portahepatic
lymph nodes also demonstrated low T2 signal intensity
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(Fig. 1). Imaging findings of iron deposition in the bone
marrow were revealed on T1 in-phase GRE imaging and
also had not been present on the previous examination
(Fig. 2). Routine pre-contrast T1 GRE images demonstrated
increased signal intensity in the blood pool and abdominal
organs, which masked normal enhancement after gadolinium
was administered (Fig. 2). The constellation of findings was
based on T1 and T2 shortening effects from ferumoxytol,
which rendered the study non-diagnostic. The patient also
had recently undergone unenhanced MRI of the brain to
evaluate the progressive cognitive decline 1 day before the
abdominal MRI, which demonstrated diffuse low signal
intensity along the surface of the brain on T2* GRE images,
findings also related to ferumoxytol administration that mim-
ic superficial siderosis (Fig. 3). The patient provided in-
formed consent for publication.
Discussion
Ferumoxytol (marketed in Europe as Rienso and North
America as Feraheme by Takeda Inc. and AMAG
Pharmaceuticals) has recently been approved in Europe and
North America for the parenteral treatment of iron deficiency
anaemia in patients with chronic kidney disease [1–3].
Parenteral iron therapy can be used safely to treat iron
deficiency anaemia in patients with chronic kidney disease
and other chronic diseases and represents an attractive alter-
native to oral iron therapy with more effective results based
on a recent systematic review [4]. Feraheme or Rienso (30-
mg/ml, ferumoxytol) is to be administered as an undiluted
intravenous (IV) injection delivered at a rate of up to 1 ml/s
(30 mg/s) for a total dose of 510 mg IV followed by a second
510-mg IV injection 2 to 8 days later [1]. Improved outcomes
when compared to oral therapy [4] and intravenous bolus
injection compared to other parenteral iron suspensions that
require longer infusions will likely lead to increased use of
ferumoxytol in clinical practice [5].
Ferumoxytol is a haematinic agent that consists of an
ultrasmall superparamagnetic iron oxide (SPIO) core coated
with a carbohydrate shell to help isolate the bioactive iron
from plasma elements until it is taken up by the reticuloen-
dothelial system (RES) macrophages of the liver, spleen and
bone marrow [1]. Ferumoxytol, similar to other SPIO agents,
results in T1, T2 and T2* shortening effects withMRI, which
can impact image interpretation and clinical practice [5]. The
pharmaceutical composition of ferumoxytol (SPIO encased
in carbohydrate shell) results in a prolonged circulating half-
life (14–15 h) in the intravascular space (blood pool), which
can alter the relaxivity characteristics of the blood pool for
days to months [5]. The T1 shortening effects and extremely
long intravascular half-life of ferumoxytol render it particu-
larly problematic with the use of traditional gadolinium-
enhanced GRE pulse sequences. Extracellular gadolinium
Fig. 1 Coronal (a) and axial (b) T2 single shot fast spin echo (ssFSE)
images (TE 90/TR 1400) demonstrate marked reduction in signal in-
tensity of the liver and spleen. Portahepatic lymph nodes (white arrow
in b) also demonstrate low T2 signal intensity. Axial T2 ssFSE image
from baseline MRI performed 15 months prior (c) demonstrates normal
signal intensity of the liver, spleen and portal lymph nodes (black arrow
in c), which are barely perceptible on this non-fat suppressed image.
Low signal intensity in the liver, spleen and lymph nodes in a and b is
due to ferumoxytol, which was administered just prior to the examina-
tion. Also note the morphologic features of cirrhosis, splenomegaly and
a small volume of peri-hepatic fluid
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agents also rely on T1 shortening effects, which can be
masked after patients have received ferumoxytol, potentially
rendering examinations non-diagnostic. This effect has been
recently reported [5] and occurred in our case. This effect
could have further implications in other areas of MRI requir-
ing the use of gadolinium for diagnosis including breast and
cardiac imaging. Furthermore, failure to appreciate that
ferumoxytol has been administered could result in the erro-
neous diagnosis of iron overload (haemosiderosis or
haemochromatosis) in the abdomen. In our patient, superfi-
cial siderosis in the brain could have been erroneously diag-
nosed on GRE images of the brain presumably related to
ferumoxytol accumulation in the leptomeninges. A key to
diagnosis if the history of the ferumoxytol injection is not
known or not provided is findings of enhancement of the
blood pool on pre-contrast GRE sequences. Low signal
intensity of lymph nodes on both T1 GRE and T2 pulse
sequences is also an indicator that the patient may have
received ferumoxytol, although this could also be seen with
calcification.
The T1 shortening properties and prolonged intravascular
half-life of ferumoxytol could represent an alternative to
enhanced MRI in patients with compromised renal function
who are at risk for nephrogenic systemic fibrosis when using
traditional gadolinium contrast agents that are cleared by the
Fig. 2 Axial pre- (a) and post-gadolinium (b) fat-suppressed T1 gra-
dient recalled echo (GRE) images (1.7/4.3) show no appreciable change
in the signal intensity of the blood pool or abdominal organs (liver,
spleen) after gadolinium injection (b) due to the pre-existing T1 short-
ening effects of ferumoxytol, which masks the T1 shortening effects of
gadolinium. This interaction renders the post-gadolinium images non-
diagnostic. Note enhancement of gastroesophageal varices on both pre-
and post-contrast images (white arrows). Axial T1 in-phase GRE image
(2.3/4.3) performed prior to gadolinium injection (c) also depicts T1
shortening effects in the liver and spleen (which masks expected pro-
found hypointensity based on T2 signal) and blood pool. Note the
marked hypointensity of the bone marrow (M) in (c) due to marrow
uptake of ferumoxytol when compared to the baseline axial T1 GRE (d)
image performed 15 months earlier, which demonstrates normal mar-
row (M) signal intensity
Fig. 3 Axial T2* GRE image (40/3000) demonstrates low signal
intensity along the surface of the brain (white arrows) presumably
related to ferumoxytol accumulation within the leptomeninges. The
appearance could easily be misinterpreted as superficial siderosis the
history of ferumoxytol administration is not known
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kidneys [6]. Ferumoxytol, like other SPIO agents, is not
cleared by glomerular filtration but by macrophages in the
RES, and this feature could also serve to help detect pathol-
ogy in the RES where normal uptake is not observed, such as
in the diagnosis of metastatic lymphadenopathy [7].
The ferumoxytol package insert warns of potential MRI
effects lasting for up to 3 months [5]. A recent prospective
study that monitored iron clearance from the liver in patients
receiving ferumoxytol showed a wide variability in iron
clearance times ranging from 3 months to 11 months, with
several participants showing persistent T2 shortening effects
after 11 months [7].
Based on our local experience and the limited information
available in the literature, our institution has developed
guidelines for radiologists and non-radiologist physicians
to consider when ordering, prescribing or interpreting MRI
studies in patients receiving ferumoxytol. For patients who
require MRI with anticipated treatment with ferumoxytol, it
is suggested that the patient undergo MRI prior to initiation
of therapy. For patients who have recently received the
medication and require gadolinium-enhanced MRI, it is sug-
gested that the exam be deferred for 3 months or that another
imaging modality (such as computed tomography) be con-
sidered as an alternative where appropriate. For patients who
have recently received ferumoxytol and require MRI without
gadolinium, each case should be considered individually
with anticipated problems likely occurring mostly in those
pathologies that involve organs of the RES.
The potential interaction of ferumoxytol with clinical
MRI studies can impact interpretation and is important for
both radiologists and non-radiologist physicians to appreci-
ate when requesting and interpreting MRI examinations for
their patients. The recent administration of ferumoxytol can
mask enhancement and render MRI examinations non-
diagnostic. Furthermore, ferumoxytol can mimic disease
states such as haemosiderosis or superficial siderosis. This
interaction is under-reported and poorly understood by radi-
ologists and the medical community at large. Increased use
of ferumoxytol in patients with chronic illness and iron
deficiency is expected and will result in a greater occurrence
of potential interactions with MRIs.
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